A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
Secretive AI drug hunter Xaira dips toe into dealmaking with hunt for partners Read More »
HouseCalls has been accused of generating trumped up diagnoses to hike UnitedHealth’s Medicare reimbursement. But the review found almost 97% of diagnoses found in the home visits were backed up by patients’ medical records, UnitedHealth said.
Vera Therapeutics’ atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA approval.
Vera moves into growing kidney disease space with FDA’s accelerated IgAN nod Read More »
El cerebro libera dopamina de forma más intensa ante un resultado incierto que ante uno seguro. Este mecanismo, ligado al núcleo accumbens, explica por qué la incertidumbre resulta tan estimulante para la mente humana. La dopamina y el circuito de recompensa a …
Por qué el cerebro humano reacciona con tanta intensidad ante la incertidumbre del azar Read More »
Ascension beat out other offers, including from HCA and Optum, to give Williamson a financial lifeline amid serious challenges facing regional hospital operators. The deal is expected to be final by 2028 at the latest.
Ascension to buy Tennessee system Williamson Health in $1B deal Read More »
A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.
The medical device supplier said that a threat actor accessed company systems through a social engineering attack.
AdaptHealth discloses patient data was stolen in cyberattack Read More »
The medical device supplier said that a threat actor accessed company systems through a social engineering attack.
AdaptHealth discloses patient data was stolen in cyberattack Read More »
New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.
New data from a Phase 3 trial will further support a rolling submission for Compass Pathways’ psilocybin treatment COMP360. Patients who saw a clinically meaningful benefit on depression severity maintained response through week 26.
Compass’ psilocybin depression drug works for the long haul Read More »
